Smith Nephew Introduces The First, Pocket-sized, Canister-free, Portable Negative Pressure Wound Therapy System In The EU
The Advanced Wound Management division of Smith & Nephew, (LSE: SN; NYSE: SNN) today announced the CE Mark approval for PICO, an effective, single-use, Negative Pressure Wound Therapy (NPWT) system for acute and chronic wounds, high-risk surgical incisions and skin grafts. PICO allows effective fluid management directly through the dressing, eliminating canisters and expanding negative pressure to a wider number of patients. PICO is now available throughout the European Union (EU) and was officially unveiled at the European Wound Management Association (EWMA) conference taking place in Brussels, Belgium [25-27 May].
New Four Year STELARA reg; Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis
New findings presented from pooled analyses of the STELARA ® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment. Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient populations on three continents and found that the efficacy and safety of STELARA in patients of Japanese and Korean-Taiwanese descent were consistent with findings previously reported in North American and European populations.
New Four Year STELARA R Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis
New findings to be presented from pooled analyses of the STELARA ® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.1 Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient populations on three continents and found that the efficacy and safety of STELARA in patients of Japanese, Korean and Taiwanese descent were consistent with findings previously reported in North American and European populations.